Compare Merck & Co., Inc. (MRK) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Western Alliance Bancorporation — how do they compare? Merck & Co., Inc. trades at $146.38 (market cap $351.28B), while Western Alliance Bancorporation trades at $74.46 (market cap $8.24B). The key difference: Merck & Co., Inc. is far larger — about 42.6× Western Alliance Bancorporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Western Alliance Bancorporation for 3 Days on average.
| MRK | WAL | |
|---|---|---|
Market Cap | $351.28B | $8.24B |
Volume | 7,969,665 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $156.43 | $96.08 |
52-Week Low | $82.49 | $66.70 |
Typical Hold Time | 98 Days | 3 Days |
Enterprise Value | $398.04B | $9.76B |
Dividend Yield | 2.39% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Western Alliance Bancorporation (WAL) trades at $74.41, showing minimal daily movement with a 0.08% gain. The stock presents compelling valuation metrics with a P/E of 8.52 and P/B of 1.09, while maintaining strong profitability with 25.43% net income margin. Recent Q2 2026 earnings matched expectations at $2.36 EPS, though technical indicators signal bearish momentum with resistance at $76-78 levels. The company continues to expand its digital banking platform with the recent WA VenueX launch.
WAL offers value investment potential with analyst consensus price target of $84.33 representing 13% upside. Strong institutional accumulation and 79% buy ratings support the bullish case, though bearish technical signals and potential regulatory changes for banks present near-term headwinds. The improving cash flow trend from -$500M to +$3.2B net cash flow in 2026 indicates strengthening financial position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
